Abstract

The Cancer and Leukemia Group B (CALGB) Statistical Center located at Duke University has primary responsibility for all statistical, data management, computing, and related activities for the CALGB. Faculty and staff statisticians and data coordinators collaborate closely with study chairs, committee chairs, and other investigators on the design, conduct, analysis, and reporting of all clinical trials and other studies conducted by the CALGB. The Statistical Center has responsibility for central data quality control and database administration. All clinical data are sent to the Statistical Center for editing, verification, and entry into the official CALGB database. Scientific laboratory data are transmitted electronically and become part of the official record. Statisticians and data coordinators from the Statistical Center are assigned to each CALGB study. They work closely with study chairs to monitor the studies and to prepare all necessary reports, analyses, and manuscripts.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA033601-28
Application #
7253200
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1982-12-01
Project End
2009-03-31
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
28
Fiscal Year
2007
Total Cost
$5,064,881
Indirect Cost

  Institution

Name
Duke University
Department
Biostatistics & Other Math Sci
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705

  Publications

McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Innocenti, Federico; Jiang, Chen; Sibley, Alexander B et al. (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Le-Petross, Huong T; McCall, Linda M; Hunt, Kelly K et al. (2018) Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). AJR Am J Roentgenol 210:669-676
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Wang, Xiaofei; Wang, Xiaoyi; Hodgson, Lydia et al. (2017) Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist 22:189-198
Zhang, Qiang; Freidlin, Boris; Korn, Edward L et al. (2017) Comparison of futility monitoring guidelines using completed phase III oncology trials. Clin Trials 14:48-58
Kohman, Leslie J; Gu, Lin; Altorki, Nasser et al. (2017) Biopsy first: Lessons learned from Cancer and Leukemia Group B (CALGB) 140503. J Thorac Cardiovasc Surg 153:1592-1597
Larsen, Jeremy T; Shanafelt, Tait D; Leis, Jose F et al. (2017) Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. Am J Hematol 92:759-763
Smith, Sonali M; Pitcher, Brandelyn N; Jung, Sin-Ho et al. (2017) Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol 4:e176-e182

Showing the most recent 10 out of 534 publications